Interleukin 2 in the management of acute leukaemia

Foà, Robin

doi:10.1046/j.1365-2141.1996.270834.x

Cited by 15 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33 Rather surprisingly, despite the wealth of phase I and phase II information, there has never been a convincing phase III study that has shown its effect post remission in AML. Several such cooperative group studies have been launched but have closed early due to inadequate patient accrual.…”

Section: Il-2mentioning

confidence: 99%

Treatment of acute myelogenous leukemia in older adults

Rowe

2000

Leukemia

View full text Add to dashboard Cite

Section: Il-2mentioning

confidence: 99%

Treatment of acute myelogenous leukemia in older adults

Rowe

2000

Leukemia

View full text Add to dashboard Cite

“…Therefore, IL-2 was tested in clinical trials for its potential to induce antileukemia immune responses as a nonspecific active immunotherapy approach (Table 1). A significant increase in activated T cells and NK cells was detected in patients with relapsed or refractory AML following high-dose IL-2 administration, as well as a few complete remissions [44]. However, this treatment regimen was associated with severe toxicity, including thrombocytopenia [45].…”

Section: Administration Of Interleukin-2mentioning

confidence: 99%

Immunotherapy of Acute Myeloid Leukemia: Current Approaches

2009

View full text Add to dashboard Cite

Following standard therapy that consists of chemotherapy with or without stem cell transplantation, both relapsed and refractory disease shorten the survival of acute myeloid leukemia (AML) patients. Therefore, additional treatment options are urgently needed, especially to fight residual AML cells. The identification of leukemia-associated antigens and the observation that administration of allogeneic T cells can mediate a graftversus-leukemia effect paved the way to the development of active and passive immunotherapy strategies, respectively. The aim of these strategies is the eradication of AML cells by the immune system. In this review, an overview is provided of both active and passive immunotherapy strategies that are under investigation or in use for the treatment of AML. For each strategy, a critical view on the state of the art is given and future perspectives are discussed.

show abstract

“…[5][6][7][8] The central role of IL-2 in initiating and sustaining immunologic reactions has led to extensive studies of its possible anti-tumor effect when delivered systemically or locally. [9][10][11][12][13][14] A number of different adherent cell elements have been characterized from long term bone marrow cultures (LTBMCs). These cells form the framework of the bone marrow microenvironment and are a heterogeneous population including fibroblastoid stromal cells, adipocytes, osteogenic cells, macrophages, myelomonocytic/lymphocytic cells, and endothelial cells accompanied by abundant extracellular matrix.…”

Section: Introductionmentioning

confidence: 99%

Adenoviral Mediated Interleukin-2 Gene Transfer to Human Long-term Bone Marrow Stromal Cultures

Hicks

Keoshkerian

French

et al. 2001

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Human long-term bone marrow stromal cultures (LTBMC) have been transduced to express the immunostimulatory cytokine interleukin-2 (IL-2). LTBMC were established from normal bone marrow and characterized by gross morphology, immunohistochemistry, immunophenotyping, and immunofluorescent staining. A stromal marrow cell (SMC) population expressing the markers CD68, CD29, CD13, and CD54 was identified. These cells were successfully transduced with an adenoviral vector containing the human IL-2 gene. Production of IL-2 was demonstrated for at least 13 days post-transduction and was maximal on day 10 at 19,350 pg (or 38 IU) of IL-2/10(6) cells/24 h. IL-2 expressed by the transduced SMC was demonstrated to be biologically active, resulting in the proliferation of autologous T lymphocytes in a mixed lymphocyte reaction. Autologous human LTBMC can be obtained and manipulated with relative ease and may be a useful vehicle for sustained local cytokine delivery.

show abstract

Interleukin 2 in the management of acute leukaemia

Cited by 15 publications

References 47 publications

Treatment of acute myelogenous leukemia in older adults

Treatment of acute myelogenous leukemia in older adults

Immunotherapy of Acute Myeloid Leukemia: Current Approaches

Adenoviral Mediated Interleukin-2 Gene Transfer to Human Long-term Bone Marrow Stromal Cultures

Contact Info

Product

Resources

About